Karyopharm is seeking a Manager/Senior Manager, IT Infrastructure & Operations to serve as a senior individual contributor owning the architecture, reliability, and evolution of the company’s infrastructure environment, reporting to the VP, Information Technology. This is a hands-on role operating with a high degree of autonomy, partnering across IT, Security, and the business to design and run scalable, secure infrastructure across a mix of cloud and legacy systems in a regulated environment.
This individual will lead complex initiatives end-to-end, drive modernization, and improve operational maturity across cloud and on-prem environments. Operating within a lean IT team, the role requires strong ownership, hands-on execution, and the ability to mentor others and influence infrastructure strategy without direct people management.
Key Responsibilities
Technical Leadership & Execution
Infrastructure Strategy & Modernization
Operational Excellence & Reliability
Security, Compliance & Risk Management
Cross-Functional Collaboration & Influence
Required Qualifications
Preferred Certifications
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. NEXPOVIO® (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
Karyopharm Therapeutics Inc. (the "Company") is an equal opportunity employer. All qualified applicants will be considered without regard to age, race, color, sex, religion/creed, national origin, marital status, ancestry, citizenship, military, reservist or veteran status, pregnancy, sexual orientation or preference, gender identity, gender expression, physical or mental disability, genetic predisposition or carrier status, or any other category protected under applicable federal, state or local law. Consistent with its obligations under applicable law, the Company will make reasonable accommodation for qualified individuals with disabilities. If you require accommodation in the application process, please contact a member of the Company’s Human Resources department.
Software Powered by iCIMS
www.icims.com